Study title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Start Date
May 24, 2019
End Date
May 26, 2025
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Start Date
May 24, 2019
End Date
May 26, 2025